Home › Funds › D. E. Shaw & Co › TSHA
D. E. Shaw & Co position in TSHA
TAYSHA GENE THERAPIES INC · Health Care
Latest position (Q2 2026)4.40M sh
Reported value held$29.95M
Portfolio Weight0.02%
First reportedQ1 2022
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2022 | 74.73K | $487.00K | New |
| Q2 2022 | 134.59K | $501.00K | Add |
| Q3 2022 | 107.27K | $207.00K | Reduce |
| Q2 2025 | 401.51K | $927.49K | New |
| Q3 2025 | 2.71M | $8.85M | Add |
| Q4 2025 | 4.01M | $22.07M | Add |
| Q1 2026 | 4.43M | $19.79M | Add |
| Q2 2026 | 4.40M | $29.95M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding TSHA
- Goldman Sachs Group 22.71M sh · $154.68M · Q2 2026
- BlackRock Inc 20.69M sh · $140.91M · Q2 2026
- Morgan Stanley 16.49M sh · $112.28M · Q2 2026
- Fidelity Management & Research (FMR) 13.34M sh · $90.82M · Q2 2026
- Vanguard Group 13.27M sh · $72.97M · Q4 2025
- Geode Capital Management 6.56M sh · $44.69M · Q2 2026
- Wellington Management Group 3.98M sh · $27.07M · Q2 2026
- Casdin Capital 3.25M sh · $22.13M · Q2 2026
- Farallon Capital Management 2.25M sh · $15.32M · Q2 2026
- Norges Bank Investment Management 2.23M sh · $15.21M · Q2 2026
- Northern Trust Corp 2.23M sh · $15.16M · Q2 2026